Fellow Health has closed a $24 million Series B financing round to expand its mail-in semen analysis services for fertility and post-vasectomy testing. The US-based company targets the traditionally overlooked male reproductive health market through clinical-grade, at-home testing solutions.
5AM Ventures led the round, with new participation from The Forest Road Company. The funding brings Fellow Health’s total capital raised to $48 million across all rounds, building on previous Series A and follow-on funding.
The company operates through a network of more than 2,500 fertility and urology practices across the United States, processing over 400 patient samples daily through its CLIA-certified laboratory. Fellow Health positions itself as the only mail-in fertility test with peer-reviewed validation data, addressing inconveniences of traditional clinic-bound testing.
“Male reproductive health shouldn’t be reactive or inaccessible,” said Brian Hogan, CEO of Fellow Health. “We are on track to deliver over 40% year-over-year revenue growth, with a path to profitability in our fertility segment by 2026.”
The funding will accelerate expansion of Fellow Health’s clinical partner network and deepen its footprint in fertility markets. The company plans to expand into employer-sponsored fertility benefits and broader access initiatives, leveraging insights from its success in urology practices.
Fellow Health has delivered over 50,000 test results this year, demonstrating demand for improved patient experiences in male reproductive health. The company’s mail-in testing provides privacy, convenience, and timely results while reducing burden on healthcare providers.
“Fellow Health is exactly the kind of company we look for—operating in a large, overlooked market that’s long overdue for disruption,” said Bill Burkoth, Managing Partner, Life Sciences at Forest Road, who will join Fellow Health’s Board of Directors as part of the financing.
Founded in 2018, Fellow Health addresses gaps in male reproductive health testing through comprehensive mail-in solutions. The company’s approach targets traditional testing methods that remain archaic and clinic-bound despite rising demand for male reproductive care.
“At 5AM, we back science that redefines what’s possible in healthcare, and Fellow Health is doing exactly that,” said Andy Schwab, Managing Partner of 5AM Ventures and Fellow Health Board Member. “They’ve taken a traditionally overlooked segment of reproductive health and applied the same rigor and precision that occurs at a traditional clinic.”
The investment reflects growing recognition of male factor infertility. Fellow Health’s platform addresses this market through improved accessibility and patient experience while maintaining clinical accuracy.
